Applications

1541 – Micro-bypass glaucoma surgery (MBGS) device implantation as a standalone procedure in patients with open-angle glaucoma (OAG)

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type -
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

New MBS item

Service or technology in this application

Micro-bypass glaucoma surgery (MBGS) devices describe a variety of ocular stents and scaffolds which, when placed in specific anatomical positions within the eye, aim to increase aqueous humour outflow, and reduce intraocular pressure. The proposed service describes the delivery of a MBGS stent which is pre-loaded on an inserter and implanted ab interno, via a corneal incision, into the trabecular meshwork or suprachoroidal space of the eye. The service is intended for individuals with primary open-angle glaucoma and is intended to be delivered as an independent procedure, not in conjunction with cataract surgery.

Medical condition this application addresses

Glaucoma is a chronic degenerative optic neuropathy characterised by progressive visual field loss due to the loss of retinal ganglion cells and optic nerve damage. Primary open-angle glaucoma describes glaucoma in which disease is the primary disease of the eye with no associated conditions or diseases (primary) and the drainage channels for aqueous humour in the front of the eye appear open (open-angle.).

Type: Therapeutic

Previous applications

1496 – Micro-bypass stenting for open-angle glaucoma (external to Schlemm's canal)
1483 – Micro-bypass stenting for open-angle glaucoma (in trabecular meshwork)

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: 5 October 2018
  • MSAC meeting: 
    • 22 to 23 November 2018
    • 1 to 2 August 2019

Stakeholder meeting

Monday 4 March 2019, the Chair of MSAC, representatives of the applicants; clinicians with expertise in ophthalmology; a representative of a consumer organisation and representatives from the Department of Health met to discuss MBGS device implantation as a standalone procedure in patients with open-angle glaucoma. This was not an MSAC decision forum, but a meeting that would inform the issues considered by MSAC, following its November 2018 consideration of application 1541. The final minutes of this meeting are above.